Mitochondrial targeted therapies in MAFLD

被引:0
|
作者
Lai, Sien [1 ]
Tang, Dongsheng [1 ]
Feng, Juan [1 ]
机构
[1] Foshan Univ, Guangdong Prov Engn & Technol Res Ctr Gene Editing, Sch Med, Foshan 528000, Peoples R China
关键词
MAFLD; Mitochondria; Targeted therapy; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; URSODEOXYCHOLIC ACID; HEPATIC STEATOSIS; INSULIN-RESISTANCE; PYRUVATE CARRIER; BILE-ACIDS; RESPIRATORY-CHAIN; CONTROLLED-TRIAL; DYSFUNCTION;
D O I
10.1016/j.bbrc.2025.151498
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a clinical-pathological syndrome primarily characterized by excessive accumulation of fat in hepatocytes, independent of alcohol consumption and other well-established hepatotoxic agents. Mitochondrial dysfunction is widely acknowledged as a pivotal factor in the pathogenesis of various diseases, including cardiovascular diseases, cancer, neurodegenerative disorders, and metabolic diseases such as obesity and obesity-associated MAFLD. Mitochondria are dynamic cellular organelles capable of modifying their functions and structures to accommodate the metabolic demands of cells. In the context of MAFLD, the excess production of reactive oxygen species induces oxidative stress, leading to mitochondrial dysfunction, which subsequently promotes metabolic disorders, fat accumulation, and the infiltration of inflammatory cells in liver and adipose tissue. This review aims to systematically analyze the role of mitochondria-targeted therapies in MAFLD, evaluate current therapeutic strategies, and explore future directions in this rapidly evolving field. We specifically focus on the molecular mechanisms underlying mitochondrial dysfunction, emerging therapeutic approaches, and their clinical implications. This is of significant importance for the development of new therapeutic approaches for these metabolic disorders.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Mitochondrial Targeted Therapies: Where Do We Stand in Mental Disorders?
    Ben-Shachar, Dorit
    Ene, Hila M.
    BIOLOGICAL PSYCHIATRY, 2018, 83 (09) : 770 - 779
  • [2] Mitochondrial dysfunctions associated with chronic respiratory diseases and their targeted therapies: an update
    Chellappan, Dinesh Kumar
    Dharwal, Vivek
    Paudel, Keshav Raj
    Jha, Niraj Kumar
    MacLoughlin, Ronan
    Oliver, Brian G.
    M Hansbro, Philip
    Dua, Kamal
    FUTURE MEDICINAL CHEMISTRY, 2021, 13 (15) : 1249 - 1251
  • [3] Overcoming mitochondrial oxidative phosphorylation-mediated resistance to targeted therapies in melanoma
    Yennu-Nanda, Vashisht Gopal
    Hu, Zeping
    Thiele, Victoria M.
    Heffernan, Tim
    DiFrancesco, Maria
    Marszalek, Joe
    Deberadinis, Ralph
    Davies, Michael A.
    MOLECULAR CANCER RESEARCH, 2016, 14
  • [4] Mitochondrion-targeted RNA therapies as a potential treatment strategy for mitochondrial diseases
    Chernega, Timofei
    Choi, Jaehyoung
    Salmena, Leonardo
    Andreazza, Ana Cristina
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2022, 30 : 359 - 377
  • [5] Mitochondrial dysfunction in Alzheimer's disease: a key frontier for future targeted therapies
    Wang, Shuguang
    Liao, Zuning
    Zhang, Qiying
    Han, Xinyuan
    Liu, Changqing
    Wang, Jin
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [6] Mitochondrial-targeted therapies in traumatic brain injury: From bench to bedside
    Tabassum, Sidra
    Wu, Silin
    Lee, Chang-Hun
    Yang, Bosco Seong Kyu
    Gusdon, Aaron M.
    Choi, Huimahn A.
    Ren, Xuefang S.
    NEUROTHERAPEUTICS, 2025, 22 (01)
  • [7] Mitochondrial Dysfunction in the Pathogenesis of Rett Syndrome: Implications for Mitochondria-Targeted Therapies
    Shulyakova, Natalya
    Andreazza, Ana C.
    Mills, Linda R.
    Eubanks, James H.
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2017, 11
  • [8] Targeted therapies
    Loriot, Y.
    ONCOLOGIE, 2013, 15 (7-8) : 387 - 389
  • [9] Targeted Therapies
    Talevi, Alan
    Castro, Guillermo R.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2017, 17 (03) : 186 - 187
  • [10] Targeted therapies
    Schlag, P. M.
    ONKOLOGE, 2007, 13 (01): : 7 - 7